Navigation Links
Doxorubicin alone or with ifosfamide for treating soft tissue sarcoma?
Date:3/25/2014

An EORTC study published in The Lancet Oncology does not support administration of intensified doxorubicin and ifosfamide for palliation of advanced soft tissue sarcoma, unless the objective is to shrink the tumor.

Dr. Ian Judson of the Royal Marsden Hospital in London and coordinator of this study says, "Our clinical trial was designed to compare combination treatment with doxorubicin and ifosfamide to treatment with doxorubicin alone, and our results show that the combination chemotherapy did not improve overall survival. So, if the goal of treatment is to control the disease, then administering doxorubicin alone is appropriate. On the other hand, if the goal is to shrink the tumor before another intervention or to relieve symptoms, then combination treatment is justifiable. The observed lack of improvement in overall survival points to the need for better treatments for patients with this disease."

For some thirty years, patients with soft tissue sarcomas have been treated with doxorubicin and ifosfamide, but few studies have directly assessed whether doxorubicin should be administered alone or in combination with ifosfamide. EORTC trial 62012 assessed whether the addition of ifosfamide to doxorubicin improves survival of patients with advanced soft-tissue sarcoma compared with doxorubicin alone.

Between April 2003 and May 2010, EORTC trial 62012 randomized 455 patients aged 18 to 60 years with unresectable locally advanced or metastatic high-grade soft-tissue sarcoma to receive either doxorubicin alone (228 patients) or intensified doxorubicin plus ifosfamide (227 patients, combination group) as first-line treatment. At a median follow-up of 56 months in the doxorubicin alone group and 59 months in the combination group, no significant difference was observed in median overall survival (12.8 months [955% CI 105 - 143] in the doxorubicin alone group and 14.3 months [12.5 16.5] in the combination group; hazard ratio [HR] 0.83 [95.5% CI 0.67 - 1.03]; stratified logrank test p = 0.076). Median progression-free survival was significantly higher in the combination group (7.4 months [95% CI 6.6 8.3]) than for the doxorubicin alone group (4.6 months [2.9 - 56]; HR 0.74 [95% CI 0.60 0.90], stratified log-rank test p = 0.003). More patients in the doxorubicin and ifosfamide group than in the doxorubicin alone group had an overall response (26% versus 14%; p < 0.0006).

The most common grade 3 and 4 toxic effects were all more common in the combination than in the doxorubicin alone group: leucopenia (43% versus 18%), neutropenia (42% versus 37%), febrile neutropenia (46% versus 13%), anemia (35% versus 5%), and thrombocytopenia (33% versus <1%).


'/>"/>

Contact: John Bean
john.bean@eortc.be
European Organisation for Research and Treatment of Cancer
Source:Eurekalert

Related medicine news :

1. Loneliness, Living Alone Might Shorten Life
2. Obesity Alone May Not Hurt Kids Classroom Performance
3. Early use of stents better than medical therapy alone for certain patients
4. Cancer-causing gene alone doesnt trigger pancreatic cancer, Mayo-led study finds
5. With food insecurity rising in US, SNAP benefits should be left alone
6. Assessment of HPV DNA alone insufficient to identify HPV-driven head and neck cancers
7. Want to Get Rid of That Old Tattoo? Youre Not Alone
8. Malecare and CancerMatch.com announce the launch of Facing Cancer Alone
9. Using mouthrinse reduces plaque and gingivitis more than toothbrushing alone
10. Affordable care alone may not be enough to help Latinos overcome cancer care barriers
11. Hate Other Peoples Cellphone Calls? Youre Not Alone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... , ... January 20, 2017 , ... “The Angel”: ... Lord has set out for each of his children. “The Angel” is the creation ... of Music in New York City, and impassioned writer. , When asked of her ...
(Date:1/20/2017)... ... ... in Suffolk”: a story of love, secrets, and mystery. “Christmas in Suffolk” is ... works in a daycare and looks for inspiration in the local coffee shop as ... Seymour’s new book is an adventure of love and secrets. , After ...
(Date:1/20/2017)... ... January 20, 2017 , ... “God's Miracle Man: Against ... Odds” is the creation of published author, Keith C. A. Tucker, son of Minister ... Fellowship World Outreach pastured by Reverend Mark Hardy , “While sitting up in bed, ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... 5,000 SF expansion and facility enhancement of their 503A compounding pharmacy located in ... the growing demand of physicians and patients throughout the United States for high-quality ...
(Date:1/19/2017)... ... January 19, 2017 , ... WhoHaha , a digital media ... American Heart Association (AHA) to produce a three-part video series that uses humor to ... part of the launch of AHA’s Healthy For Good™ movement, which is designed to ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 19, 2017 The global immunomodulators market ... 2025, according to a new study by Grand ... be predominantly driven by high R&D investments employed ... production of new and therapeutically advanced drugs. This ... at an unprecedented rate into the immunomodulators market ...
(Date:1/19/2017)... Jan. 19, 2017 The Global Therapy Partnering ... access to partnering deals and agreements entered into by ... partnering deals - Top deals by value - Deals ... technology type The report provides understanding and access ... the world,s leading healthcare companies. The report provides ...
(Date:1/19/2017)... 19, 2017 Conference Call and Webcast to Follow ... announced it will release results for the fourth quarter of 2016 ... ... conference call at 4:30 PM ET on Wednesday, February 15, 2017, ... 2016 financial results and other corporate activities. To participate in the ...
Breaking Medicine Technology: